使用维布妥昔单抗靶向CD30治疗霍奇金淋巴瘤
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
作者信息
Alperovich Anna, Younes Anas
机构信息
From the Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
Cancer J. 2016 Jan-Feb;22(1):23-6. doi: 10.1097/PPO.0000000000000168.
Abstract
The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.
摘要
CD30受体的表达是霍奇金淋巴瘤（HL）恶性里德-斯腾伯格细胞的决定性特征之一。正常细胞很少表达CD30，且其会迅速内化，这使其成为单克隆抗体和抗体药物偶联物的理想治疗靶点。维布妥昔单抗是首个获监管机构批准用于治疗复发HL患者的抗体药物偶联物，单药有效率为75%。在这篇综述文章中，我们讨论了维布妥昔单抗在复发和新诊断HL患者中的当前及正在进行的研发情况。
相似文献
1
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Cancer J. 2016 Jan-Feb;22(1):23-6. doi: 10.1097/PPO.0000000000000168.
2
Brentuximab vedotin.
Blood. 2014 Nov 20;124(22):3197-200. doi: 10.1182/blood-2014-06-537514. Epub 2014 Oct 7.
3
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
J Hematol Oncol. 2014 Mar 19;7:24. doi: 10.1186/1756-8722-7-24.
4
Anti-CD30 Antibodies for Hodgkin lymphoma.
Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y.
5
The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Acta Med Indones. 2018 Apr;50(2):93-95.
6
Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Future Oncol. 2020 Oct;16(29):2273-2282. doi: 10.2217/fon-2020-0026. Epub 2020 Jul 17.
7
CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Curr Hematol Malig Rep. 2016 Dec;11(6):480-491. doi: 10.1007/s11899-016-0345-y.
8
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14.
9
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
10
Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
Hematol Oncol Clin North Am. 2014 Feb;28(1):27-32. doi: 10.1016/j.hoc.2013.10.005.
引用本文的文献
1
Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment.
Biomark Med. 2025 Mar;19(6):223-238. doi: 10.1080/17520363.2025.2471745. Epub 2025 Feb 27.
2
Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.
Pathogens. 2023 Dec 22;13(1):14. doi: 10.3390/pathogens13010014.
3
Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma.
Front Immunol. 2023 Jan 26;14:1068662. doi: 10.3389/fimmu.2023.1068662. eCollection 2023.
4
[Relapsed Hodgkin lymphoma with only breast involvement: a rare case report].
Pan Afr Med J. 2022 May 12;42:29. doi: 10.11604/pamj.2022.42.29.35083. eCollection 2022.
5
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.
Mar Drugs. 2021 Aug 27;19(9):488. doi: 10.3390/md19090488.
6
Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model.
Biomacromolecules. 2021 Oct 11;22(10):4169-4180. doi: 10.1021/acs.biomac.1c00662. Epub 2021 Sep 20.
7
Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma.
Cancers (Basel). 2021 Jul 20;13(14):3634. doi: 10.3390/cancers13143634.
8
Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Jpn J Clin Oncol. 2020 Oct 22;50(11):1265-1273. doi: 10.1093/jjco/hyaa117.
9
Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens.
J Clin Pharmacol. 2020 Dec;60(12):1585-1597. doi: 10.1002/jcph.1682. Epub 2020 Jun 28.
10
Hodgkin Lymphoma Mimicking Inflammatory Breast Carcinoma: A Rare Case with Diagnostic Challenge and Novel Treatment.
Case Rep Hematol. 2019 Dec 5;2019:9256807. doi: 10.1155/2019/9256807. eCollection 2019.
本文引用的文献
1
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
Haematologica. 2015 Jul;100(7):e269-71. doi: 10.3324/haematol.2015.124784. Epub 2015 Apr 3.
2
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
3
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13.
4
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
5
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17.
6
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
7
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.
Zotero 插件